Trial reportCell reports. Medicine2026
Stereotactic body radiotherapy plus sunitinib vs. sunitinib alone in treatment-naive oligometastatic renal cell carcinoma: A phase 2 clinical trial.
Trial report in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Comparative data on stereotactic body radiotherapy (SBRT) in oligometastatic renal cell carcinoma (RCC) is lacking. This single-center, phase 2 non-randomized controlled trial enrolls patients with treatment-naive oligometastatic RCC. Patients choose to receive sunitinib alone (control arm, n = 24) or plus SBRT (SBRT arm, n = 24). The primary endpoint, objective response rate (83.3% vs. 29.2%; p < 0.001), is higher in the SBRT arm. With a median follow-up of 40.6 months, the 1-year local control rate is 91.5%. Progression-free survival (PFS) is significantly longer in the SBRT arm (17.3 vs. 6.3 months; p = 0.036). Post hoc multivariable analysis shows that SBRT significantly prolongs PFS (hazard ratio [HR], 0.42; 95% confidence interval [CI], 0.21-0.84; p = 0.015). Grade 3 toxicities are similar (54.2% vs. 50.0%, p = 0.773). The SBRT arm shows a trend toward better quality of life. These suggest potential benefit of SBRT in oligometastatic RCC, requiring further validation by phase 3 trials. The trial is registered at Chictr.org.cn (ChiCTR1800017136).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.